Escitalopram in the treatment of major depressive disorder: A meta-analysis

References

• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-52
   PubMed Web of Science ®Google Scholar
• Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med 1998;17:841-56
   PubMed Web of Science ®Google Scholar
• Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7(Supp 1):11-17
   PubMedGoogle Scholar
• Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36
   PubMed Web of Science ®Google Scholar
• Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001;57:161-78
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RI. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41
   PubMed Web of Science ®Google Scholar
• Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007;62:1217-27
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Nelson JC, Kasper S, et al. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2008;18:122-7
   PubMed Web of Science ®Google Scholar
• Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007;27:672-6
   PubMed Web of Science ®Google Scholar
• Nemeroff CN, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63:424-34
   PubMed Web of Science ®Google Scholar
• Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004;19:149-155
   PubMed Web of Science ®Google Scholar
• Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002;7(4 Supp 1):40-4
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Lam R. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-31
   PubMed Web of Science ®Google Scholar
• Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 2006;39:180-4
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-7
   PubMed Web of Science ®Google Scholar
• Sánchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 2006;99:91-5
   PubMed Web of Science ®Google Scholar
• Chen F, Larsen MB, Sánchez C, et al. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005;15:193-8
   PubMed Web of Science ®Google Scholar
• Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• ICH harmonized tripartite guideline (E9). Statistical principles for clinical trials. (1998). Available at http://www. emea.europa.eu/pdfs/human/ich/036396en.pdf (accessed September, 2008)
   Google Scholar
• Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Invest 2007;27:481-92
   PubMed Web of Science ®Google Scholar
• Wade AG, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007;23:1605-14
   PubMed Web of Science ®Google Scholar
• Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 1997;53:983-97
   PubMed Web of Science ®Google Scholar
• Carmody TJ, Rush AJ, Bernstein I, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006;16:601-11
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-17
   PubMed Web of Science ®Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-6
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Bose, A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65:44-9. See also: http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_SCT-MD-02_final.pdf. (accessed September, 2008)
   PubMed Web of Science ®Google Scholar
• Colonna L, Andersen HF, Reines EH. A randomised, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005;21:1659-68
   PubMed Web of Science ®Google Scholar
• Mao PX, Tang YL, Jiang F, et al. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depress Anxiety 2008;25:46-54
   PubMed Web of Science ®Google Scholar
• Kasper S, de Swart H, Andersen HF. Escitalopram in the treatment of depressed elderly patients. Am J Geriat Psychiatry 2005;13:884-91
   PubMed Web of Science ®Google Scholar
• Forest Laboratories, 2001. Flexible dose comparison of the safety and efficacy of escitalopram and fluoxetine in the treatment of major depressive disorder. Available at http://www. forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_ file_id=scsr/SCSR_SCT-MD-16_final.pdf (accessed September, 2008)
   Google Scholar
• Baldwin DS, Cooper JA, Huusom AK, et al. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006;21:159-69
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Huusom AKT, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006;22:1331-41
   PubMed Web of Science ®Google Scholar
• Ventura D, Armstrong EP, Skrepnek GH, et al. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin 2007;23:245-50
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Gordon J, Zhang D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Neuropsychopharmacology 2004;29 (Suppl):S87. See also: http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_SCT-MD-27_final.pdf (accessed September, 2008)
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Ventura D, Chang C-C. A double-blind comparison of escitalopram with venlafaxine XR in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-6
   PubMed Web of Science ®Google Scholar
• Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006;67:736-46
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007;23:401-16
   PubMed Web of Science ®Google Scholar
• Lalit V, Prakash A, Rajendra H, et al. Escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in Indian patients with unipolar depression. Ind J Psychiatry 2004;46:333-41
   PubMedGoogle Scholar
• Khan MNS. Comparison of escitalopram a new SSRI with TCA, clomipramine in major depressive disorder: a double blind study. Pak J Med Sci 2004;20:238-41
   Google Scholar
• Li J, Shen WW, Liu Y, et al. The effectiveness and safety of escitalopram in the treatment of major depression: a randomized double-blind active-drug controlled trial. Chin J Evid-based Med [Zhongguo xunzheng yixue zazhi] 2006;6:552-6. [Article in Chinese]
   Google Scholar
• Lancon C, Sapin C, Note I, et al. Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: a prospective, naturalistic, 8-week study. Int J Psychiatry Clin Prac 2006;10:131-7
   PubMed Web of Science ®Google Scholar
• Yevtushenko VY, Belous AI, Yevtushenko YG, et al. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. J Clin Ther 2007;29:2319-32
   PubMed Web of Science ®Google Scholar
• Eli Lilly & Co (2007). Personal communication
   Google Scholar
• Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006;21:297-309
   PubMed Web of Science ®Google Scholar
• Lam RW, Andersen HF, Wade AG. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. Int Clin Psychopharmacol 2008;23:181-7
   PubMed Web of Science ®Google Scholar
• Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry 2006;39:128-34
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007;62:1217-27
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007;22:323-9
   PubMed Web of Science ®Google Scholar
• Le Poul E, Laaris N, Doucet E, et al. Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn Schmiedebergs Arch Pharmacol 1995;352:141-8
   PubMed Web of Science ®Google Scholar
• Rossi DV, Burke TF, Hensler JG. Differential regulation of serotonin-1A receptor-stimulated [35S]GTPγS binding in the dorsal raphe nucleus by citalopram and escitalopram. Eur J Pharmacol 2008;583:103-7
   PubMed Web of Science ®Google Scholar
• Anderson IM. Commentary on ‘Re-evaluation of the efficacy and tolerability of venlafaxine versus SSRI: meta-analysis’ by Weinmann. Psychopharmacology (Berl) 2008;196:521-2
   Web of Science ®Google Scholar